Varenicline and Nicotine Interactions in Humans (VA)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To examine the effects of varenicline on the subjective, physiological and cognitive
responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is
approved as a treatment for smoking cessation. We predict that varenicline treatment will
modify subjective, physiological and cognitive responses to IV nicotine.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) US Department of Veterans Affairs VA Office of Research and Development